The molecular mechanisms underlying uveitis (intraocular inflammation) are poorly understood, a major barrier to progress in treating the disease or designing specific therapeutics. This proposal builds on our exciting discovery that Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV; a type of uveitis) can be caused by mutations in the cysteine protease CAPN5 (calpain-5), one member of a family of proteins that uses proteolysis to control a spectrum of molecular events. Thus, CAPN5 is the first nonsyndromic uveitis gene to be identified, which now makes possible a highly innovative molecular-genetic approach to identifying the factors responsible for intraocular inflammation, neovascularization, and fibrosis. The long-term goals of our research are to identify new therapeutic targets for uveitis. Our objective in this proposal is to identify the structure-functin mechanism of calpain-5 mutations that activate molecular pathways leading to uveitis and probe inhibitor interactions. Our central hypothesis is that ADNIV mutations increase calpain-5 proteolytic activity and are amenable to structure guided inhibition that will eventually be used t prevent retinal inflammation. Our rationale is that, intracellular calpain-5 activity is normally a tightly controlled proteolytic switch for activating signaling molecules, and when calpain-5 is hyperactive, target signals are tripped pathogenically. Excess calpain activity has been implicated in the pathogenesis of a wide range of human diseases including cancer, multiple sclerosis, Alzheimer's disease, diabetes, and muscular dystrophy. Although little is known about CAPN5, our preliminary studies suggest ADNIV disease mutants increase CAPN5 enzymatic activity through structural changes and alter cellular transcription.
Our specific aims are to test the hypotheses that: (1) ADNIV mutants alter CAPN5 catalytic and proteolytic activity in vitro; (2) CAPN5 and ADNIV residues affect activity of other calpains; and (3) ADNIV mutations alter CAPN5 structure using circular dichroism spectroscopy, small angle x-ray scattering SAXS, and crystallization. We will use novel enzymatic methods and modeling to pursue studies that trace the molecular mechanism of CAPN5 mutations. Our work should have a significant positive impact on identifying new molecular mechanisms for therapeutic intervention of uveitis. At the completion of these experiments, we expect to have in hand a CAPN5 catalytic activity assays that can ultimately be used for low and high-throughput drug screening. We also expect to resolve the structure of the protein, which will expose differences between CAPN5 and its orthologs. Since the ADNIV phenocopies other eye diseases, our studies promise to have a broad positive impact, beyond ADNIV and uveitis patients, where components of the CAPN5 pathway may be therapeutic targets.

Public Health Relevance

ADNIV is an inherited eye disease caused by mutations in calpain-5 that cause uveitis. Discovery of the structure-function mechanisms will help to understand and treat blinding diseases caused by intraocular inflammation.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY024665-02
Application #
8975771
Study Section
Biophysics of Neural Systems Study Section (BPNS)
Program Officer
Mckie, George Ann
Project Start
2014-12-01
Project End
2019-11-30
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Iowa
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52246
Velez, Gabriel; Tang, Peter H; Cabral, Thiago et al. (2018) Personalized Proteomics for Precision Health: Identifying Biomarkers of Vitreoretinal Disease. Transl Vis Sci Technol 7:12
Liu, Katherine Y; Sengillo, Jesse D; Velez, Gabriel et al. (2018) Missense mutation in SLIT2 associated with congenital myopia, anisometropia, connective tissue abnormalities, and obesity. Orphanet J Rare Dis 13:138
DiCarlo, James E; Mahajan, Vinit B; Tsang, Stephen H (2018) Gene therapy and genome surgery in the retina. J Clin Invest 128:2177-2188
Jauregui, Ruben; Thomas, Amanda L; Liechty, Benjamin et al. (2018) SCAPER-associated nonsyndromic autosomal recessive retinitis pigmentosa. Am J Med Genet A :
Cho, Galaxy Y; Schaefer, Kellie A; Bassuk, Alexander G et al. (2018) CRISPR GENOME SURGERY IN THE RETINA IN LIGHT OF OFF-TARGETING. Retina 38:1443-1455
Wu, Wen-Hsuan; Tsai, Yi-Ting; Justus, Sally et al. (2018) CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa: A Brief Methodology. Methods Mol Biol 1715:191-205
Cabral, Thiago; Lima, Luiz H; Mello, Luiz Guilherme M et al. (2018) Bevacizumab Injection in Patients with Neovascular Age-Related Macular Degeneration Increases Angiogenic Biomarkers. Ophthalmol Retina 2:31-37
Roybal, C Nathaniel; Velez, Gabriel; Toral, Marcus A et al. (2018) Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell Recruitment and mTOR as a Therapeutic Target. Am J Ophthalmol 186:152-163
Wert, Katherine J; Velez, Gabriel; Cross, Madeline R et al. (2018) Extracellular superoxide dismutase (SOD3) regulates oxidative stress at the vitreoretinal interface. Free Radic Biol Med 124:408-419
Evans, Lucy P; Newell, Elizabeth A; Mahajan, MaryAnn et al. (2018) Acute vitreoretinal trauma and inflammation after traumatic brain injury in mice. Ann Clin Transl Neurol 5:240-251

Showing the most recent 10 out of 38 publications